Plasmapheresis in multifocal motor neuropathy: a case report

Claus, D.

doi:10.1136/jnnp.68.4.533

Cited by 42 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma exchange,39, 57, 68, 124 immunoadsorption,58 and CSF filtration59 are similarly ineffective in most reported patients with MMN and marginally effective in a few of them 18, 84, 133, 163. In occasional patients, plasma exchange was rapidly followed by severe clinical worsening and by the appearance of CB in previously clinically unaffected motor nerves 33, 41, 133. These findings highlight the fact that the distinction between MMN and CIDP or Lewis–Sumner syndrome is not purely of theoretical interest, because steroids and plasma exchange, which are usually effective in CIDP and Lewis–Sumner syndrome, are ineffective or even dangerous in MMN.…”

Section: Therapy Of Mmnmentioning

confidence: 99%

Multifocal motor neuropathy: Current concepts and controversies

2005

View full text Add to dashboard Cite

Multifocal motor neuropathy (MMN) is now a well-defined purely motor multineuropathy characterized by the presence of multifocal partial motor conduction blocks (CB), frequent association with anti-GM1 IgM antibodies, and usually a good response to high-dose intravenous immunoglobulin (IVIg) therapy. However, several issues remain to be clarified in the diagnosis, pathogenesis, and therapy of this condition including its nosological position and its relation to other chronic dysimmune neuropathies; the degree of CB necessary for the diagnosis of MMN; the existence of an axonal form of MMN; the pathophysiological basis of CB; the pathogenetic role of antiganglioside antibodies; the mechanism of action of IVIg treatments in MMN and the most effective regimen; and the treatment to be used in unresponsive patients. These issues are addressed in this review of the main clinical, electrophysiological, immunological, and therapeutic features of this neuropathy.

show abstract

Section: Therapy Of Mmnmentioning

confidence: 99%

Multifocal motor neuropathy: Current concepts and controversies

2005

View full text Add to dashboard Cite

show abstract

“…The unusual feature of our two patients was the paradoxical motor deterioration after PE. In contrast, potential deterioration after PE in multifocal motor neuropathy is a widely accepted notion ( Carpo et al, 1998; Claus et al, 2000 ) . A hypothesis advanced to explain this clinical worsening after PE was that PE removed anti‐idiotypic antibodies, either free or bound in immunocomplexes with the pathogenic antibody(ies) that were in turn bound in immunocomplexes with the antigen, thus creating an imbalance between high‐affinity pathogenic and low‐affinity protective autoantibodies.…”

Section: Nerve Conduction Studies*mentioning

confidence: 99%

Two patients with CIDP deteriorated following plasma exchange

Larue

Dashi

Demeret

et al. 2008

J Peripheral Nervous Sys

View full text Add to dashboard Cite

“…The treatment options for people with MMN are sparse. In contrast to the response in CIDP, MMN does usually not respond to steroids or plasma exchange, and patients may worsen when they receive these treatments [7,[52][53][54].…”

Section: Treatment Of Mmnmentioning

confidence: 99%

European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy*

Schaik

Bouché

Illa

et al. 2006

Euro J of Neurology

View full text Add to dashboard Cite

Several diagnostic criteria for multifocal motor neuropathy have been proposed in recent years and a beneficial effect of intravenous immunoglobulin (IVIg) and various other immunomodulatory drugs has been suggested in several trials and uncontrolled studies. The objectives were to prepare consensus guidelines on the definition, investigation and treatment of multifocal motor neuropathy. Disease experts and a patient representative considered references retrieved from MEDLINE and the Cochrane Library in July 2004 and prepared statements which were agreed in an iterative fashion. The Task Force agreed good practice points to define clinical and electrophysiological diagnostic criteria for multifocal motor neuropathy and investigations to be considered. The principal recommendations and good practice points were: (i) IVIg (2 g/kg given over 2-5 days) should be considered as the first line treatment (level A recommendation) when disability is sufficiently severe to warrant treatment. ObjectivesTo construct guidelines for the definition, diagnosis and treatment of multifocal motor neuropathy (MMN) based on the available evidence and, where adequate evidence was not available, consensus.

show abstract

Plasmapheresis in multifocal motor neuropathy: a case report

Cited by 42 publications

References 4 publications

Multifocal motor neuropathy: Current concepts and controversies

Multifocal motor neuropathy: Current concepts and controversies

Two patients with CIDP deteriorated following plasma exchange

European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy*

Contact Info

Product

Resources

About